PMID- 31587590
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jan
TI  - Immune checkpoint inhibition for the treatment of renal cell carcinoma.
PG  - 83-94
LID - 10.1080/14712598.2020.1677601 [doi]
AB  - Introduction: The systemic therapy in metastatic renal cell carcinoma (mRCC) is 
      moving from tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin 
      (mTOR) inhibitors to immune checkpoint inhibitors and its combination with 
      TKIs.Areas covered: This review provides a general overview using immune 
      checkpoint inhibition for the treatment of RCC. Clinical results from conducted 
      and ongoing clinical trials are summarized and checkpoint inhibition is reviewed 
      in the context to other available systemic therapies such as TKIs for mRCC based 
      on the different International Metastastic RCC Database Consortium (IMCD) risk 
      groups. Furthermore, prospects for the use of predictive biomarkers in the 
      decision-making process of chosen therapy will be given.Expert opinion: Using 
      checkpoint inhibition in mRCC has demonstrated a superior efficacy for patients 
      with IMDC intermediate and poor risk for ipilimumab combined with nivolumab. 
      Furthermore, therapeutic regimes with tyrosine kinase inhibition plus immune 
      checkpoint-inhibition were recently presented and demonstrated superiority in all 
      risk groups for axitinib plus pembrolizumab in overall survival and 
      progression-free survival (PFS) and axitinib plus avelumab in PFS compared to 
      sunitinib monotherapy. Novel biomarkers of response to further optimize 
      therapeutic selection and patient outcomes are ongoing medical objectives.
FAU - Stuhler, Viktoria
AU  - Stuhler V
AD  - Department of Urology, University of Tubingen, Tubingen, Germany.
FAU - Maas, Jan Moritz
AU  - Maas JM
AD  - Department of Urology, University of Tubingen, Tubingen, Germany.
FAU - Rausch, Steffen
AU  - Rausch S
AD  - Department of Urology, University of Tubingen, Tubingen, Germany.
FAU - Stenzl, Arnulf
AU  - Stenzl A
AD  - Department of Urology, University of Tubingen, Tubingen, Germany.
FAU - Bedke, Jens
AU  - Bedke J
AUID- ORCID: 0000-0003-2778-3108
AD  - Department of Urology, University of Tubingen, Tubingen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191013
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Renal Cell/*drug therapy/metabolism
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/metabolism
MH  - Protein Kinase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Biomarker
OT  - CTLA-4
OT  - PD-1
OT  - PD-L1
OT  - checkpoint inhibition
OT  - renal cell carcinoma
EDAT- 2019/10/08 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/10/08 06:00
PHST- 2019/10/08 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/10/08 06:00 [entrez]
AID - 10.1080/14712598.2020.1677601 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2020 Jan;20(1):83-94. doi: 10.1080/14712598.2020.1677601. 
      Epub 2019 Oct 13.